Form 4: Amneal Pharmaceuticals EVP Jason Daly Reports Stock Transactions
SEC Form 4 Filing
Jason Daly, EVP and Chief Legal Officer of Amneal Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.
Summary
- Jason Daly, EVP and Chief Legal Officer of Amneal Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- The transactions involved Class A Common Stock and Restricted Stock Units (RSUs).
- On March 3, 2025, Daly acquired shares through the vesting of RSUs and Performance-Based Restricted Stock Units, and disposed of shares to cover tax obligations.
- On March 4, 2025, Daly acquired shares through the vesting of RSUs and disposed of shares to cover tax obligations.
- Daly also received a grant of 194,064 Performance-Based Restricted Stock Units and 97,032 Restricted Stock Units on March 3, 2025.
- The price per share for shares disposed of to cover tax obligations was $8.76 on March 3, 2025 and $8.84 on March 4, 2025.
Sentiment
Score: 7
Explanation: The document reflects routine transactions related to executive compensation. The vesting of performance-based RSUs suggests the company is meeting certain performance targets, which is a mildly positive signal.
Positives
- The vesting of restricted stock units and performance-based restricted stock units indicates that the company is meeting certain performance metrics or time-based vesting schedules.
Future Outlook
The document outlines future vesting schedules for restricted stock units and performance-based restricted stock units, indicating potential future equity compensation payouts.
Industry Context
Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing is typical for executives receiving and managing equity compensation.
Comparison to Industry Standards
- Equity compensation is a common practice in the pharmaceutical industry to align executive interests with shareholder value.
- Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Sun Pharmaceutical Industries also utilize restricted stock units and performance-based awards as part of their executive compensation packages.
- The vesting schedules and performance metrics associated with these awards are often benchmarked against industry peers to ensure competitiveness and effectiveness.
Stakeholder Impact
- The transactions have a minor impact on shareholders, as they reflect the standard equity compensation practices for executives.
- Employees may view the vesting of performance-based RSUs as a positive sign of company performance.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2022 | Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. |
| 03/03/2023 | Reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/04/2024 | Reporting Person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/03/2025 | Date of earliest transaction reported; vesting of RSUs and Performance-Based RSUs. |
| 03/04/2025 | Date of transaction reported; vesting of RSUs. |
| 03/05/2025 | Date of filing. |
| 03/03/2026 | Restricted stock units vest in four equal annual installments beginning on this date. |
| 02/28/2028 | Any earned performance-based restricted stock units vest in full on this date, the last day of the performance period. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.